HPV prevalence and type distribution in women with or without cervical lesions in the Northeast region of Romania

Virology Journal

Luminiţa-Smaranda Iancu¹  Dragoş Nemescu²  Mircea Onofriescu²  Ramona Gabriela Ursu¹ 

[1] Microbiology Department, "Grigore T. Popa" University of Medicine and Pharmacy, Universitatii Str. NO 15, Iaşi 700115, Romania;Gynecology Department, "Grigore T. Popa" University of Medicine and Pharmacy, Iaşi, Universitatii Str. NO 15, Iaşi 700115, Romania

关键词: Vaccination;    Persistence;    Prevalence;    Cytology;    Screening;    HPV;   

Others  :  1155361
DOI  :  10.1186/1743-422X-8-558

 received in 2011-07-28, accepted in 2011-12-22,  发布年份 2011

【 摘 要 】

Background

Cervical cancer is a major public health problem worldwide. While Romania has the highest incidence of cervical cancer in Europe, the prevalence of HPV has not been evaluated. We report the first data on HPV prevalence and type distribution in Northeast Romania.

Methods

HPV prevalence and genotype distribution was investigated in 514 consecutively women with or without cervical lesions in Northeast Romania. Genotyping was performed with Linear Array Genotyping/Roche kit.

Results

In our study group, 192/514 (37.4%) patients were positive for HPV (infected with single and with multiple HPV types). Most frequent types were: 16 (10.5%), 53 (5.44%), 51 (5.05%), 52 (4.08%) 18 (2.91%) and 31 (2.73%).

Conclusions

Infection with high risk types of HPV is common in Northeast Romania. Enhanced and systematic screening for cervical cancer is needed. Our results call for the implementation of a National HPV vaccine program in Romania.

【 授权许可】

   
2011 Ursu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004, 324(1):17-27.
• [2]Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
• [3]Muňoz N, Bosch X, de Sanjosé S, et al.: Epidemiologic classification of Human Papilloma Virus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
• [4]Bosch XF, Qiao YL, Castellsagué X: The epidemiology of human papillomavirus infection and its association with cervical cancer. Int J Gynaecol Obstet 2006, 94:(Supplement 1):S8-S21.
• [5]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base. [http://globocan.iarc.fr] webcite 2010.
• [6]WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human Papillomavirus and Related Cancers in World. [http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/KEN.pdf] webciteSummary Report 2009.
• [7]Bosoteanu M, Bosoteanu C, Deacu M, Aschie M: The importance of monitoring protocols in cervical carcinoma screening. Rom J Morphol Embryol 2011, 52(1 Suppl):297-302.
• [8]de Sanjose , et al.: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2001, 7(7):453-459.
• [9]Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P, Prendiville W: European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2009, 20(1):5-16.
• [10]Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, Gasperov NM, Grce M, Tachezy R: Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol 2008, 46(5):1606-13.
• [11]Eklund C, Zhou T, Dillner J: WHO Human Papillomavirus Laboratory Network., Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010, 48(11):4147-55. Epub 2010 Sep 15
• [12]Anttila A, Ronco G: Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009, 45(15):2685-708.
• [13]Badulescu F, Prejbeanu I, Rada C, Patrascu A, Dragomir M, Popescu FC: Evaluation of women knowledge and attitude regarding cervical cancer early detection. Rom J Morphol Embryol 2011, 52(1):45-51.
• [14]Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-110.
• [15]Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl 10):K29-41. Review
• [16]Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ: Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009, 46(Suppl 3):S1-4.
• [17]Anttila A, von Karsa L, Aasmaa A, Fender M, Patnick J, Rebolj M, Nicula F, Vass L, Valerianova Z, Voti L, Sauvaget C, Ronco G: Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009, 45(15):2649-58.
• [18]Apostol I, Baban A, Nicula F, Suteu O, Coza D, Amati C, Baili P: EUROCHIP Working Group. Cervical cancer assessment in Romania under EUROCHIP-2. Tumori 2010, 96(4):545-52.
• [19]Arbyn M, Primic-Zakelj M, Raifu AO, Grce M, Paraskevaidis E, Diakomanolis E, Kesic V, Nicula FA, Suteu O, von Karsa L: The burden of cervical cancer in south-east Europe at the beginning of the 21st century. Coll Antropol 2007, 31(Suppl 2):7-10.
• [20]Arbyn M, Antoine J, Valerianova Z, Mägi M, Stengrevics A, Smailyte G, Suteu O, Micheli A: Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania. Tumori 2010, 96(4):517-23.
• [21]Nicula FA, Anttila A, Neamtiu L, Zakelj MP, Tachezy R, Chil A, Grce M, Kesic V: Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur J Cancer 2009, 45(15):2679-84.
• [22]Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197(4):346-55.
• [23]de Sanjosé S, Quint WGV, Alemany L, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-56.
• [24]Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E: Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004, 57:68-72.